X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
REACT, a renal autologous homologous cell admixture, is made from expanded autologous SRCs, obtained from each individual subject’s kidney biopsy. REACT is currently in a Phase 3 development program for Diabetic Kidney Disease.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
REACT, a renal autologous homologous cell admixture, is made from expanded autologous SRCs, obtained from each individual subject’s kidney biopsy. REACT is currently in a Phase 3 development program for Diabetic Kidney Disease.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases possibly drive meaningful improvement in kidney function.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
REACT is an autologous cell therapy produced from a patient’s own kidney cells that is comprised of a proprietary mixture of progenitor cells that have been selected and cultured so they can be placed back into the patient’s kidney to restore the natural healing processes.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
The primary objective of this study is to assess the safety and efficacy of up to two REACT (Renal Autologous Cell Therapy) injections delivered into biopsied and non-biopsied contralateral kidneys using a minimally invasive percutaneous approach.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential not only to slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
ProKidney’s lead product candidate, REACT® (Renal Autologous Cell Therapy), has the potential to not only slow the progression of CKD, but in some cases drive meaningful improvement in kidney function – a groundbreaking first in CKD therapies.
Lead Product(s): Renal Autologous Cell Therapy
Therapeutic Area: Nephrology Product Name: REACT
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Social Capital Suvretta Holdings Corp. III
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
